Research article · 2016
Conference abstract
Screening methods to reduce adverse statin effects
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
With more than 25 years of clinical trial data cholesterol-lowering statin drugs are used as the first-line treatment for prevention and treatment of cardiovascular disease. Currently statins are among the most widely prescribed drugs. The occurrence of statin adverse events (AEs) was underestimated in clinical trials. In November 2013 the American Heart Association and the American College of Cardiology published new guidelines that are expected to expand statin use. Gene variations have been identified that modify statin response and increase susceptibility to statin AEs (e.g. SLCO1B1, CoQ2, variants in liver transport genes, variants in drug metabolism). Over the last decade Dr. Golombâ??s group investigated statin AEâ??s, both those reported in patients that were enrolled in the UCSD Statin Effects Study (patient-targeted AE surveillance); and in the UCSD Statin Study (>1000 person randomized double-blind placebo controlled trial). For the former, >5000 patient surveys were submitted, including patient contact information and willingness to be contacted, and these data sets are available for further analysis, with the majority of participants expressing willingness to subjects that reported AEs as well as unaffected controls that previously participated in the UCSD Statin Study. The goal would be to develop predictive models, including questionnaires and pharmacogenomic screening before initiation of statin therapy as well as follow up questionnaires, by which statin therapy/drug choice may be tailored based on the patientâ??s genetic profile. The hope would be to move toward safer prescribing, to reduce the adverse effect toll from this widely used drug class.
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Research article · 31 Oct 2015
Chromatographic and spectrophotometric method for estimation of statin class drugs in bulk and in different dosage forms
Review article · 18 Apr 2023
Study Protocol for a Phase II/III, Randomised, Placebo-Controlled Clinical Trial of Reducing the Frequency of Autoimmune Adverse Events in the Treatment of Multiple Sclerosis with Alemtuzumab using B Cell Depletion: The RAMBLE Trial
Research article · 31 Oct 2022
Medication Reconciliation Led by Clinical Pharmacist as an Effective Strategy in Preventing and Reducing Adverse Drug Reactions
Commentary · 2018
Pharmacovigilance in the Long-Term use of Medications and the Alternative Based on the Combination of Drugs to Reduce Adverse Effects
More from this journal
The newest in Journal of Pharmacogenomics & Pharmacoproteomics.
Article · 31 Dec 2025
Molecular Phenotyping: Integrated Biological Profiles for Understanding Cellular Function and Disease
Article · 31 Dec 2025
Genetic Determinants of Individual Drug Response
Article · 31 Dec 2025
Genetic Variation in Drug Metabolism, Transport, and Treatment Response
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Pharmacogenomics & Pharmacoproteomics
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Alice E Zemljic-Harpf”

